会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Relax gas discharge laser lithography light source
    • 放气放电激光光刻光源
    • US20050083983A1
    • 2005-04-21
    • US10956784
    • 2004-10-01
    • Richard SandstromWilliam PartloDaniel BrownThomas YagerAlexander ErshovRobert RafacGerman Rylov
    • Richard SandstromWilliam PartloDaniel BrownThomas YagerAlexander ErshovRobert RafacGerman Rylov
    • B23K26/06B23K26/40G01J1/42G01J9/02G02B26/00G02B26/08G03F7/20H01S20060101H01S3/00H01S3/1055H01S3/22H01S3/225
    • G01J1/429B23K26/0622B23K2101/40G01J9/02G02B26/002G02B26/0875G03F7/70041G03F7/70575H01S3/005H01S3/0057H01S3/1055H01S3/225
    • An apparatus and method are disclosed for operating a narrow band short pulse duration gas discharge laser output light pulse beam producing system, producing a beam comprising laser output light pulses at a selected pulse repetition rate, which may comprise: a dispersive center wavelength selection optic selecting at least one center wavelength for each pulse determined at least in part by the angle of incidence of the laser light pulse beam containing the respective pulse on the dispersive wavelength selection optic; a tuning mechanism operative to select at least one angle of incidence of a first spatially defined portion of the laser light pulse beam containing the respective pulse upon the dispersive center wavelength selection optic; and, the tuning mechanism comprising a variably refractive optical element defining a plurality of refractive angular displacements of the first spatially defined portion of the laser light pulse beam passing through the variably refractive optical element at one of a plurality of positions of incidence of the laser light pulse beam on the variably refractive optical element. The variably refractive optical element may comprise: a first generally flat face defining a surface of incidence for the laser light pulse beam; and, a second multifaceted or curved face defining a plurality of generally flat surfaces of exit or a continuously varying surface of exit for the laser light beam. Other aspects of pulse parameter metrology and pulse modulation control, including in response to signals from the utilization tool are disclosed, e.g., relating to proper dose control with differing center wavelength spectra.
    • 公开了一种用于操作窄带短脉冲持续时间气体放电激光输出光脉冲束产生系统的装置和方法,产生包括选定脉冲重复频率的激光输出光脉冲的光束,其可以包括:色散中心波长选择光学选择 用于每个脉冲的至少一个中心波长至少部分地由分散波长选择光学器件上包含相应脉冲的激光束的入射角确定; 调谐机构,用于在色散中心波长选择光学器件上选择包含相应脉冲的激光束脉冲光束的第一空间限定部分的至少一个入射角; 并且所述调谐机构包括可变折射光学元件,所述可变折射光学元件限定所述激光束的所述第一空间限定部分的多个折射角位移通过所述可变折射光学元件在所述激光的入射的多个位置中的一个位置 脉冲光束在可变折射光学元件上。 可变折射光学元件可以包括:限定用于激光束脉冲束的入射面的第一大致平坦的面; 以及限定用于激光束的出口的多个大致平坦的表面或出口的连续变化的表面的第二多面或弯曲面。 脉冲参数测量和脉冲调制控制的其它方面包括响应来自利用工具的信号,例如涉及具有不同中心波长光谱的适当剂量控制。
    • 3. 发明申请
    • Method and apparatus for correlating levels of biomarker products with disease
    • 将生物标记产物与疾病相关的方法和装置
    • US20070213939A1
    • 2007-09-13
    • US11585666
    • 2006-10-23
    • Choong-Chin LiewMark HanThomas YagerSamuel ChaoRun ZhengHongwei Zhang
    • Choong-Chin LiewMark HanThomas YagerSamuel ChaoRun ZhengHongwei Zhang
    • G06F19/00
    • C12Q1/6886C12Q2600/112C12Q2600/136C12Q2600/158C12Q2600/16G06F19/12G06F19/18G06F19/20G06F19/24G16H50/30Y02A90/26
    • In one aspect the invention is a method of testing for one or more colorectal pathologies or one or more subtypes of colorectal pathology (in one embodiment colorectal cancer) in a test individual by providing data corresponding to a level of products of selected biomarkers and applying the data to a formula to provide an indication of whether the test individual has one or more colorectal pathologies or one or more subtypes of colorectal pathology. In some aspects the method is computer based and a computer applies the data to the formula. In other aspects a computer system is configured with instructions that cause the processor to provide a user with the indication of whether the test individual has colorectal pathology. Also encompassed are kits for measuring data corresponding to the products of selected biomarkers which in some embodiments include a computer readable medium. Also encompassed are kits and methods of monitoring therapeutic efficacy of treatments for one or more colorectal pathologies.
    • 在一个方面,本发明是通过提供对应于所选生物标志物的产物水平的数据并应用所述生物标志物的一个或多个结直肠病理学或一种或多种结直肠病理学亚型(在一个实施方案中为结肠直肠癌)的测试个体中的方法, 数据提供给公式,以提供测试个体是否具有一种或多种结肠直肠病变或一种或多种结直肠病理学亚型的指示。 在某些方面,该方法是基于计算机的,并且计算机将数据应用于公式。 在其他方面,计算机系统配置有指令,其使得处理器向用户提供测试个体是否具有结肠直肠病理学的指示。 还包括用于测量与所选生物标志物的产物相对应的数据的试剂盒,其在一些实施方案中包括计算机可读介质。 还包括监测一种或多种结肠直肠病变治疗效果的试剂盒和方法。
    • 4. 发明授权
    • Kits and primers for diagnosing schizophrenia
    • 用于诊断精神分裂症的试剂盒和底物
    • US08258284B2
    • 2012-09-04
    • US12777042
    • 2010-05-10
    • Choong-Chin LiewThomas YagerAdam DempseySamuel Chao
    • Choong-Chin LiewThomas YagerAdam DempseySamuel Chao
    • C07H21/04
    • C12Q1/6883C12Q2600/158Y02A90/22Y02A90/24Y02A90/26
    • The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens. The invention also provides for the identification of methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets of schizophrenia and/or bipolar disorder and a method of screening the genes of said biomarkers for additional markers of disease.
    • 本发明涉及新型生物标志物的鉴定和选择以及在血液中差异表达并可用于诊断精神分裂症和/或双相性精神障碍以及监测治疗精神分裂症或双相性精神障碍的治疗功效的新型生物标志物组合的鉴定和选择。 本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于诊断精神分裂症和/或双相性精神障碍。 使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质来测量本发明的生物标志物的产物的表达水平也包括在本发明的范围内,因为包含所述多核苷酸的组合物和试剂盒和 蛋白质。 本发明还包括使用多核苷酸和蛋白质来监测治疗方案的功效。 本发明还提供了鉴定使用本发明的生物标志物的产物在鉴定精神分裂症和/或双相性精神障碍的新型治疗靶标的方法,以及筛选所述生物标志物的基因以获得另外的疾病标志物的方法。
    • 5. 发明申请
    • Biomarkers for diagnosing schizophrenia and bipolar disorder
    • 用于诊断精神分裂症和双相情感障碍的生物标志物
    • US20090098564A1
    • 2009-04-16
    • US12287629
    • 2008-10-10
    • Choong-Chin LiewThomas YagerAdam DempseySamuel Chao
    • Choong-Chin LiewThomas YagerAdam DempseySamuel Chao
    • C12Q1/68
    • C12Q1/6883C12Q2600/158Y02A90/22Y02A90/24Y02A90/26
    • The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens. The invention also provides for the identification of methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets of schizophrenia and/or bipolar disorder and a method of screening the genes of said biomarkers for additional markers of disease.
    • 本发明涉及新型生物标志物的鉴定和选择以及在血液中差异表达并且可用于诊断精神分裂症和/或双相性精神障碍以及监测治疗精神分裂症或双相性精神障碍的治疗功效的新型生物标志物组合的鉴定和选择。 本发明的生物标志物的产物和生物标志物的组合的表达水平的测量可用于诊断精神分裂症和/或双相性精神障碍。 使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质来测量本发明的生物标志物的产物的表达水平也包括在本发明的范围内,因为包含所述多核苷酸的组合物和试剂盒和 蛋白质。 本发明还包括使用多核苷酸和蛋白质来监测治疗方案的功效。 本发明还提供了鉴定使用本发明的生物标志物的产物在鉴定精神分裂症和/或双相性精神障碍的新型治疗靶标的方法,以及筛选所述生物标志物的基因以获得另外的疾病标志物的方法。
    • 6. 发明申请
    • Computer system and methods for constructing biological classifiers and uses thereof
    • 用于构建生物分类器的计算机系统和方法及其用途
    • US20070269804A1
    • 2007-11-22
    • US10568264
    • 2005-06-20
    • Choong-Chin LiewThomas YagerAdam DempseySamuel Chao
    • Choong-Chin LiewThomas YagerAdam DempseySamuel Chao
    • C12Q1/68G06F19/00
    • G06F19/24G06F19/18Y02A90/24Y02A90/26
    • The present invention provides systems and method for constructing classifiers that distinguish between trait subgroups using molecular marker data from blood samples. The invention further encompasses the use of the classifiers and combinations of molecular markers identified by the classifiers in a wide variety of applications including: diagnosis; prognosis; prediction of disease, stage of disease or disease risk; monitoring disease progression and/or regression; monitoring disease reoccurrence and identifying risk of disease reoccurrence; determining and/or predicting response to treatment and/or treatment outcomes; monitoring and/or predicting treatment compliance or non compliance and the like. The invention further provides a variety of selected molecular markers and a means to identify combinations of the selected molecular markers useful for diagnosing particular traits of interest.
    • 本发明提供用于构建分类器的系统和方法,其使用来自血液样品的分子标记数据区分特征亚组。 本发明还包括在各种应用中使用分类器和由分类器鉴定的分子标记物的组合,包括:诊断; 预后; 疾病预测,疾病阶段或疾病风险; 监测疾病进展和/或消退; 监测疾病复发并发现疾病复发的风险; 确定和/或预测对治疗和/或治疗结果的反应; 监测和/或预测治疗依从性或不合规等。 本发明进一步提供了多种选择的分子标记和识别用于诊断感兴趣的特定性状的所选分子标记物的组合的方法。
    • 7. 发明申请
    • Mild osteoarthritis biomarkers and uses thereof
    • 轻度骨关节炎生物标志物及其用途
    • US20060263797A1
    • 2006-11-23
    • US11347944
    • 2006-02-06
    • Choong-Chin LiewHongwei ZhangAdam DempseyThomas YagerSamuel Chao
    • Choong-Chin LiewHongwei ZhangAdam DempseyThomas YagerSamuel Chao
    • C12Q1/68G01N33/567G01N33/53
    • C12Q1/6883C12Q2600/136C12Q2600/158G01N2800/102
    • The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in individuals with mild osteoarthritis as compared with individuals without osteoarthritis. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in diagnosing mild osteoarthritis. Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease regression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis.
    • 本发明涉及新生物标志物的鉴定和选择以及与没有骨关节炎的个体相比,在具有轻度骨关节炎的个体中差异表达的新型生物标志物组合的鉴定和选择。 与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质也包括在本发明的范围内,如含有用于诊断轻度骨关节炎的所述多核苷酸和蛋白质的试剂盒。 本发明进一步包括使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质,以监测个体的疾病回归并监测治疗方案的功效。 本发明还提供了使用本发明的生物标志物的产物鉴定骨关节炎的新型治疗靶标的方法。
    • 8. 发明授权
    • Method of diagnosing mild osteoarthritis
    • 诊断轻度骨关节炎的方法
    • US08483968B2
    • 2013-07-09
    • US12777140
    • 2010-05-10
    • Choong-Chin LiewHongwei ZhangAdam DempseyThomas YagerSamuel Chao
    • Choong-Chin LiewHongwei ZhangAdam DempseyThomas YagerSamuel Chao
    • G01N33/48
    • C12Q1/6883C12Q2600/136C12Q2600/158G01N2800/102
    • The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in individuals with mild osteoarthritis as compared with individuals without osteoarthritis. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in diagnosing mild osteoarthritis. Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease regression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis.
    • 本发明涉及新生物标志物的鉴定和选择以及与没有骨关节炎的个体相比,在具有轻度骨关节炎的个体中差异表达的新型生物标志物组合的鉴定和选择。 与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质也包括在本发明的范围内,如含有用于诊断轻度骨关节炎的所述多核苷酸和蛋白质的试剂盒。 本发明进一步包括使用与本发明的生物标志物的产物特异性和/或选择性杂交的多核苷酸和蛋白质,以监测个体的疾病回归并监测治疗方案的功效。 本发明还提供了使用本发明的生物标志物的产物鉴定骨关节炎的新型治疗靶标的方法。
    • 9. 发明申请
    • ALTERATION OF GRAPHENE DEFECTS
    • 石墨缺陷变化
    • US20130071616A1
    • 2013-03-21
    • US13391158
    • 2011-09-16
    • Seth MillerThomas Yager
    • Seth MillerThomas Yager
    • B32B9/04B05C3/20B32B3/10B05D5/12
    • C01B32/194B05C3/02B05C3/20B05D5/12B32B3/10B32B9/04C01B32/182C01B32/184Y10T428/24331
    • Technologies are generally described for method and systems effective to at least partially alter a defect in a layer including graphene. In some examples, the methods may include receiving the layer on a substrate where the layer includes at least some graphene and at least some defect areas in the graphene. The defect areas may reveal exposed areas of the substrate. The methods may also include reacting the substrate under sufficient reaction conditions to produce at least one cationic area in at least one of the exposed areas. The methods may further include adhering graphene oxide to the at least one cationic area to produce a graphene oxide layer. The methods may further include reducing the graphene oxide layer to produce at least one altered defect area in the layer.
    • 通常描述了有效地至少部分地改变包括石墨烯的层中的缺陷的方法和系统的技术。 在一些示例中,所述方法可以包括在衬底上接收该层,其中层包括至少一些石墨烯和石墨烯中的至少一些缺陷区域。 缺陷区域可能暴露基底的暴露区域。 所述方法还可包括在足够的反应条件下使底物反应以在至少一个暴露区域中产生至少一个阳离子区域。 所述方法还可以包括将氧化石墨烯粘附到至少一个阳离子区域以产生氧化石墨烯氧化物层。 所述方法还可以包括减少石墨烯氧化物层以在该层中产生至少一个改变的缺陷区域。